Parameters | Cell lines | Free and nano-regimens |
---|
RX | RX-CS NPs (F1) | RX-CS NPs (F2) | RX-HA-CS NPs |
---|
IC50, µM | Caco-2 cells | 64.07 | 56.31 | 61.06 | 25.45 |
HCT 116 cells | 86.79 | 45.59 | 54.10 | 40.22 |
WI-38 cells | 76.30 | ND | ND | ND |
Cytotoxic fold | Caco-2 cells | Ref. | 1.14 | 1.05 | 2.52 |
HCT 116 cells | Ref. | 1.90 | 1.60 | 2.16 |
WI-38 cells | Ref. | 0.76 | 0.76 | 0.76 |
IC50 fold | Caco-2 cells | Ref. | 0.88 | 0.95 | 0.40 |
HCT 116 cells | Ref. | 0.53 | 0.62 | 0.46 |
WI-38 cells | Ref. | ND | ND | ND |
- The cytotoxic fold change represents the IC50 of the free RX divided by the IC50 of each nano-platform to calculate the cytotoxic fold change between the RX-encapsulated nanoparticles versus the free counterpart (RX). The IC50 fold change represents the IC50 of each nano-platform divided by free RX to calculate the fold times in IC50 values between the RX-encapsulated nanoparticles compared to the free counterpart (RX)
- Caco-2 and HCT 116 cells: human colorectal cell lines, IC50 the average of colorectal cancer cell’s half inhibitory effect; RX raloxifene, HA hyaluronic acid, CS: chitosan, NPs nanoparticles